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Text message-based diabetes self-
management support (SMS4BG): study
protocol for a randomised controlled trial
Rosie Dobson1* , Robyn Whittaker1,2, Yannan Jiang1, Matthew Shepherd3, Ralph Maddison1, Karen Carter1,
Richard Cutfield2, Catherine McNamara2, Manish Khanolkar4 and Rinki Murphy4,5
Abstract
Background: Addressing the increasing prevalence, and associated disease burden, of diabetes is a priority of health
services internationally. Interventions to support patients to effectively self-manage their condition have the potential
to reduce the risk of costly and debilitating complications. The utilisation of mobile phones to deliver self-management
support allows for patient-centred care at the frequency and intensity that patients desire from outside the clinic
environment. Self-Management Support for Blood Glucose (SMS4BG) is a novel text message-based intervention
for supporting people with diabetes to improve self-management behaviours and achieve better glycaemic control
and is tailored to individual patient preferences, demographics, clinical characteristics, and culture. This study aims to
assess whether SMS4BG can improve glycaemic control in adults with poorly controlled diabetes. This paper outlines
the rationale and methods of the trial.
Methods/design: A two-arm, parallel, randomised controlled trial will be conducted across New Zealand health
districts. One thousand participants will be randomised at a 1:1 ratio to receive SMS4BG, a theoretically based and
individually tailored automated text message-based diabetes self-management support programme (intervention) in
addition to usual care, or usual care alone (control). The primary outcome is change in glycaemic control (HbA1c) at
9 months. Secondary outcomes include glycaemic control at 3 and 6 months, self-efficacy, self-care behaviours,
diabetes distress, health-related quality of life, perceived social support, and illness perceptions. Cost information
and healthcare utilisation will also be collected as well as intervention satisfaction and interaction.
Discussion: This study will provide information on the effectiveness of a text message-based self-management
support tool for people with diabetes. If found to be effective it has the potential to provide individualised support to
people with diabetes across New Zealand (and internationally), thus extending care outside the clinic environment.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12614001232628.
Keywords: mHealth, Diabetes mellitus, Text message, Mobile phone, SMS, Self-management
Background
Addressing increasing diabetes prevalence, its associated
morbidity and health inequalities, is a current priority in
New Zealand and internationally [1–4]. The burden of
diabetes is greater in indigenous peoples [1] with higher
disease prevalence and poorer outcomes seen in Māori
[5, 6]. Good diabetes self-management, including glucose
monitoring, engaging in health behaviours, insulin ad-
ministration, and healthcare provider contact, is associ-
ated with improved glycaemic control, and even small
improvements in glycaemic control are associated with
reduction in costly and debilitating long-term compli-
cations [7–12].
Mobile phones are ubiquitous, with increasing owner-
ship and use across hard-to-reach populations [13, 14].
Text message (short message service, SMS) volumes have
remained high over recent years with nearly 14 billion
SMS messages sent in New Zealand in the year ending
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June 2012 [15]. Mobile health (mHealth) is the use of
mobile devices, including mobile phones, to deliver
health services and information [16]. Mobile phones
have been used effectively to support healthy behaviour
change and disease management [17–21], and offer an
ideal way of providing patient-centred care at the fre-
quency and intensity that patients desire. In addition
there is potential for mobile phones to provide an ef-
fective way of providing support to patients in rural
and remote areas where healthcare provider contact
may be less accessible [22, 23].
There is a growing body of evidence supporting the
use of mobile phones in the management of diabetes
[24–26], with previous studies showing positive impacts
on glycaemic control [25, 27], patient satisfaction with
healthcare [25], healthcare costs [25], self-efficacy [28],
and self-management behaviours, e.g. adherence and blood
glucose monitoring [28–30]. Although promising, many
previous studies have lacked sufficient sample sizes, were
of insufficient duration, or interventions lacked theoretical
grounding. Learnings has identify that for this type of
intervention to be successful it needs to be theoretically
based [19, 31], individually tailored [22, 32–35], and to
provide individual choice to increase patients’ sense of
control [36].
In light of the increasing prevalence of diabetes in New
Zealand, as well as increasing mobile phone penetration,
we hypothesise that mobile-based tools are important op-
tions for self-management support in this population. A
mobile phone-based text messaging programme designed
to enhance self-management support for people with dia-
betes (SMS4BG: Self-Management Support for Blood Glu-
cose) has been developed and piloted [37]. Development
of the SMS4BG followed the mHealth Development and
Evaluation framework [38], with a focus on implementa-
tion, use of behavioural change theory, and engagement of
key stakeholders including clinicians and patients. Con-
ceptualisation, formative research and pretesting, includ-
ing a pilot study, have been previously reported [37, 39].
SMS4BG was developed by a multidisciplinary team
including public health and mHealth experts, psycholo-
gists, diabetes nurse specialists, a Māori advisory group,
with review and input from diabetes specialists and pri-
mary care teams. The intervention is grounded in behav-
iour change theory to enhance people’s self-efficacy [40],
and to promote accurate illness perceptions [41]. It uses
Behaviour Change Techniques (BCTs) [42] (see Additional
file 1 for a list of BCTs utilised in SMS4BG) to address the
behaviours required for successful self-management and is
made up of modules allowing for tailoring to the individ-
ual patient. The intervention content is designed to ad-
dress the seven key self-management behaviours identified
by the Association of American Diabetes Educations: (1)
healthy eating, (2) being active, (3) monitoring, (4) taking
medication, (5) problem solving, (6) reducing risks, and
(7) healthy coping [43]. In addition the intervention in-
cludes versions for Māori and Pacific peoples incorporating
concepts and elements specific to these cultures. Involve-
ment of primary and secondary care teams throughout the
development attempts to ensure integration into clinical
pathways. The pilot study found the programme accept-
able, useful, and culturally and age-appropriate [37]. Feed-
back from the SMS4BG pilot study allowed for further
development and refinement of SMS4BG including in-
creasing the duration of the programme based on patient
preference, the addition of new modules including a foot
care module and a cardiovascular check reminder module,
and increased tailoring to incorporate individual motiva-
tions and names of support people. While the pilot study
yielded positive results, a larger-scale randomised con-
trolled trial (RCT) of the effectiveness of SMS4BG is now
required including the effectiveness of SMS4BG in urban,
and rural and remote areas. The findings from this RCT
will inform the decision on whether to scale up and imple-
ment the programme across New Zealand.
Aim
This study aims to determine the effectiveness of the
mHealth diabetes self-management support programme
(SMS4BG) in adults with poorly controlled type 1 or type
2 diabetes, in addition to their usual diabetes care. Specific
objectives include:
1. Enabling improved diabetes self-management as
measured by improvements in glycosylated haemo-
globin (HbA1c)
2. Assessing the effectiveness of SMS4BG in areas with
high rural/remote populations
Methods/design
This protocol describes a 9-month, two-arm, parallel, RCT
to evaluate the effectiveness of a text message-based dia-
betes self-management support programme (SMS4BG), on
glycaemic control as measured by HbA1c. This protocol is
in accord with the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) 2013 statement
[44], and the intervention is described according to the
Consolidated Standards of Reporting Trials (CON-
SORT)-EHEALTH checklist [45]. See Additional file 2
for the completed SPIRIT checklist.
Study population and recruitment
Eligible participants are adults (aged 16 years and over)
with poorly controlled diabetes (defined as an HbA1c over
65 mmol/mol in the preceding 9 months) who own a text
message-capable mobile phone, are able to read English,
provide informed consent, and are available for the study
duration. Exclusion criteria are not being available for the
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duration of the study, or being unable to use a mobile
phone due to physical disabilities affecting eyesight or
dexterity and not having a carer who wishes to use the
mobile tools on their behalf. Recruitment for the trial
commenced June 2015.
Potential participants will be identified by clinicians
within primary and secondary care services across New
Zealand health districts. Districts will be categorised as
either high urban population or high rural/remote popu-
lation based on population destiny data. Recruitment
processes will build on those used successfully in the
pilot study with clinicians forwarding the contact details
of interested and eligible participants to the research
team who will contact the patient by phone to discuss
the study and gain informed consent. Informed consent
will be obtained from all participants before they are en-
rolled in the study.
Outcome assessments
Assessments will be conducted at baseline and 9 months
post randomisation (see Fig. 1). Baseline assessments will
involve collection of demographic information and self-
reported outcome measures via phone interview, and
collection of clinical measures via patient records. Fol-
lowing completion of baseline data collection the patient
will be randomised and, if allocated to the intervention
arm, will be asked a small number of intervention-
tailoring questions and will then be enrolled in the inter-
vention. Intervention-tailoring questions include:
 Preferred first name
 Preferred mobile number
 Preferred message delivery time (early morning:
7–9 am, mid-morning: 9 am–12 pm, early after-
noon: 12–3 pm, late afternoon: 3–5 pm, evening:
5–8 pm, or day: 9 am–5 pm)
 Region (Auckland or non-Auckland)
 Names and relationship of two support people
(partner, parent/caregiver, child, friend, other)
 Motivations for diabetes management (your family,
your whānau, your partner, your husband, your
wife, your mum, your dad, your child, your children,
your grandchild, your grandchildren, your friends,
your career, your health in the future, sport, your
fitness)
 Module choices (See Table 1).
Follow-up assessments will involve completion of self-
reported outcome measures via phone interview, and
collection of clinical measures via patient records.
Fig. 1 Study flow diagram
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Table 1 Description of SMS4BG modules
Module Description Participants Duration Example message
Core module Two messages per week providing
general motivation and support for
diabetes management. Available in
3 version:
Māori
Pacific
Non-Māori/non-Pacific
All 3 to 9 months SMS4BG: Kia ora. Control of your glucose levels
involves eating the right kai, exercise & taking
your medication. Your whānau, doctor & nurse
can help you
SMS4BG: Talofa (name). by managing your
diabetes well (including eating well and
exercising) you can show your family that
diabetes can be controlled
SMS4BG: There is no quick fix to diabetes
but with good management it will have
less impact on your life and leave you more
time to do the things you enjoy
Insulin module One educational text message per
week around insulin management
and hypos for patients receiving insulin
Available to participants
who are prescribed insulin
3 to 9 months SMS4BG: Keep unopened insulin in the fridge.
Don’t use insulin that has changed colour,
is lumpy, expired, cracked or leaking, or has
been frozen or overheated
Young adult module One message per week around
managing diabetes in the context
or work/school and social situations
Available to participants
aged 16–24
3 to 9 months SMS4BG: Unsure whether to tell your friends/
boyfriend/girlfriend about diabetes? This can
be tough but people who care about you will
want to know & support you
Smoking cessation
module
One message per month encouraging
participants to consider quitting
smoking and providing details of
services for support
All participants who
register as smokers
3 to 9 months SMS4BG: (hi) (name). Good management of
your diabetes & your future health includes
not smoking, call Quitline on 0800 778 778
for support
Lifestyle behaviour
modules
Up to 4 messages per week encouraging
participants to set a lifestyle goal and
supporting them to work towards this
goal. Participants can receive one of
these modules for 3 months. The three
lifestyle modules are:
Healthy eating
Exercise
Stress and mood
Available to all
participants
Each module
3 months
SMS4BG: Healthy eating is an important part
of your diabetes treatment and it will help
you in controlling your blood glucose levels
SMS4BG: If you are too tired to exercise at
the end of the day, try waking up early &
doing your exercise in the morning. It will
energise you for the day
SMS4BG: (hi) (name). Make sure you have
fun activities scheduled regularly. Doing
something enjoyable helps reduce stress
& improves mood
Blood glucose
monitoring
Reminders to test blood glucose, sent
at a frequency selected by the patient,
for which they are encouraged to
respond by reply text message with
their blood sugar readings. In addition
informational messages around
managing hypos.
Available to all participants
required to monitor their
blood glucose
3 to 9 months SMS4BG: (hi) (name). Just a reminder it is
time to check your blood glucose. Reply
with the result.
If valid response received to reminder,
‘SMS4BG: Thank you for sending your result’
SMS4BG: Hypoglycaemias (hypos) are when
your blood glucose drops too low (i.e. less
than 4 mmol/L). If this happens take
something with sugar immediately
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Table 1 Description of SMS4BG modules (Continued)
Foot care module Reminders and motivational messages
supporting engagement in foot care
Available to those who are
classified as high risk or
have active foot disease
3 to 9 months SMS4BG: Looking after your feet will help to
prevent issues in the future. Check your feet
daily & contact your doctor, nurse or podiatrist
if there are changes
Cardiovascular check
reminder
Reminder to engage in a yearly
cardiovascular assessment
Available to those who
qualify
3 months SMS4BG: (hi) (name). Next time you see your
doctor ask about getting a cardiovascular
check done. You should have one each year
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Ethics approval
Ethical approval for this trial was obtained from the
Health and Disability Ethics Committee (14/STH/162).
Sample size
One thousand participants (500 per arm) will be re-
cruited for the trial, stratified by the health districts with
either high urban or high rural/remote populations.
Recruiting 500 participants (250 per arm) in each of the
health district populations will provide 90 % power at
the 5 % significance level to detect an overall clinically
meaningful difference of 0.5 % (6 mmol/mol) change in
HbA1c from baseline to 9 months between the two
arms in each of the populations, assuming a standard
deviation of 1.7 %. Targeted recruitment strategies will
be used to preferentially recruit Māori and Pacific partic-
ipants where possible.
Randomisation and blinding
Eligible participants will be randomised to either interven-
tion or control group in a 1:1 ratio. Randomisation will be
stratified by health district category (high urban or high
rural/remote), diabetes type (1 or 2), and ethnicity (Māori
and Pacific, or non-Māori and non-Pacific). The random-
isation sequence will be generated by computer programme
using variable block sizes of 2 or 4, and overseen by the
study statistician (YJ). The treatment allocation will be con-
cealed until the point of randomisation. Due to the nature
of the intervention participants will be aware of their treat-
ment allocation. Although it will not be possible for re-
search staff conducting the phone interviews to be blinded
to the treatment allocation, the primary outcome HbA1c is
an objective measure and assessors of this outcome will be
blinded to treatment allocation.
Intervention
Both intervention and control groups will continue with
their usual diabetes care including all medical visits, tests,
and diabetes support programmes. In addition the inter-
vention group will receive the automated text message-
based self-management support programme (SMS4BG) for
up to 9 months. SMS4BG is tailored according to the
needs and goals of the patient, their care plan, and demo-
graphic factors including ethnicity. As well as core motiv-
ational and support messages (available in Māori, Pacific
and non-Māori/non-Pacific versions), participants can opt
to receive additional modules such as a lifestyle module
around healthy eating, physical activity or stress manage-
ment. Where appropriate to their care, they can also re-
ceive reminders to check blood glucose levels, messages
around insulin, foot care, managing diabetes as a young
adult, and smoking cessation, and also messages encour-
aging preventive behaviours (e.g. cardiovascular risk assess-
ment). Participants who opt to reply to glucose monitoring
reminders, by sending in their blood glucose levels by text
message, will be able to view their blood glucose levels
graphically over time on a secure website. If at baseline
they are identified as not having access to the Internet they
will be mailed their graphs on a monthly basis. At registra-
tion the intervention group will be able to select the timing
of their messages and blood glucose monitoring reminders,
and to identify their support people and motivations for
diabetes management for incorporation into the messages.
The length of the programme will also be tailored to patient
preferences from 3 to 9 months, and at 3 and 6 months
participants will receive a text message asking if they would
like to continue the programme for an additional 3 months
and will be given the opportunity to re-select their modules.
Participants can stop their messages at any time by texting
the word ‘STOP’, or put their messages on hold for 1 week
by sending the text word ‘HOLIDAY’. A summary of the
structure of SMS4BG can be seen in the Table 1. More de-
tail on the intervention and its development is available in
the pilot study paper [37].
The message delivery will be managed by a specifically
developed SMS4BG Content Management System with
the messages sent and received through a gateway com-
pany to allow for participants to be registered with any
New Zealand mobile network. Sending and receiving
messages will be free to all participants with costs cov-
ered by the study. The system will maintain logs of all
outgoing and incoming messages, and incoming blood
glucose values will be automatically graphed by the sys-
tem which individuals can view via a password-protected
website.
Outcome measures
The primary outcome measure is change in glycaemic
control from baseline to 9 months, measured as HbA1c
(in mmol/mol or %) by registered laboratories. Second-
ary outcome measures include:
 Glycaemic control measured by registered laboratory
measurements of HbA1c (in mmol/mol or %) at
3 months and at 6 months. Both 3-month and
6-month HbA1c results will be obtained from
patient records at the 9-month follow-up
 Self-efficacy for diabetes management measured by
the Stanford Self-efficacy for Diabetes Management
scale (SEDM) [46] at baseline and at 9 months. The
SEDM is an 8-item measure which respondents use
to indicate, on a Likert scale from 1 (not at all
confident) to 10 (totally confident), how confident
they feel that they can carry out the listed tasks
regularly at the present time. The score is calculated
using the mean of the eight items with higher scores
indicating higher self-efficacy. The SEDM has been
found to have good internal consistency and
test-retest validity [46]
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 Diabetes self-care behaviours measured by the
Summary of Diabetes Self-Care Activities [47]
(SDSCA) at baseline and at 9-month follow-up.
The SDSCA is a brief self-reported questionnaire
which asks respondents 11 items relating to five
different domains of diabetes self-management:
diet, exercise, blood-glucose monitoring, foot care,
and smoking. The SDSCA has been shown to have
good validity and reliability in research and practice
[47], with higher scores on the scale indicating greater
engagement in self-care behaviours
 The presence of diabetes-related distress measured
by the 2-item Diabetes Distress Scale (DDS2) [48] at
baseline and at 9 months. This 2-item brief diabetes
distress screening instrument detects diabetes-
specific distress. Respondents indicate, on a 6-point
Likert scale, to what degree each item has caused
them distress over the past month with higher score
indicating higher distress. The DDS2 has been
shown to discriminate highly distressed patients
from patients with low diabetes distress [48], with
an average item score of 3 or more used as the cut
off for high distress
 Cognitive and emotional representations of diabetes
measured by the Brief Illness Perception
Questionnaire (BIPQ) [49] at baseline and at
9 months. The BIPQ is a 9-item self-reported
measure which assesses consequences, timeline,
personal control, treatment control, identity, concern,
emotions, illness comprehensibility, and causes of
diabetes. Each item (except causality) is rated using an
11-point Likert scale with higher scores indicating
greater agreement with the item. The causal
representation is assessed via an open-ended item.
The BIPQ has been shown to have good reliability
and validity [49], and has previously been used in a
New Zealand diabetes population to assess differences
in illness perceptions between Europeans, South
Asians and Pacific Islanders [50]
 Health-related quality of life measured by the
EuroQol 5 dimensions (EQ-5D) questionnaire [51]
at baseline and at 9-month follow-up. The EQ-5D
provides a descriptive profile of health status and a
single index value for health status. Five dimensions
of health are assessed in the descriptive system:
mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. The respondent indicates
under each dimension their health state by choosing
the severity level most appropriate to themselves. A
lower number indicates a better health status and
quality of life. The EQ-5D visual analogue scale
allows the respondent to mark, on a scale from 0
(worst imaginable health state) to 100 (best
imaginable health state), their health state. There is
evidence to support the validity and reliability of the
EQ-5D in people with diabetes [52]
 Perceived social support for diabetes management
measured using a 4-item measure developed for this
study at baseline and at 9-month follow-up. The
measure is split into two sections. The first assesses
general support and asks how supported they feel in
regards to their diabetes management on a 6-point
Likert scale, from 1 (not at all supported) to 6
(extremely supported). The second section assesses
appraisal, emotional and advice/information aspects
of support (one item each). Users indicate, on a
6-point Likert scale ranging from 1 (strongly disagree)
to 6 (strongly agree), to what degree they agree with
the statements
 Healthcare utilisation measured by number of
hospitalisations, and primary and secondary care
visits during the study period compared to the
9 months prior to randomisation. Healthcare
utilisation will be obtained from patient records at
9-month follow-up
 Patient satisfaction and engagement with SMS4BG
(for those in the intervention group). At 9 months
participants will be asked, via semi-structured
interview, about their satisfaction with the
programme, including ease of use, issues arising,
satisfaction with the text messages, salience and
usefulness of the messages, and suggestions for
improvement. In addition the overall number of text
messages sent and received, response rates, and
intervention duration will be measured by the
SMS4BG content management system
 Cost-effectiveness of the intervention using cost
information obtained at 9 month follow-up,
including the costs of the SMS4BG programme, the
direct medical costs (including cost of treatment,
primary care, secondary care) and Quality-adjusted
Life Years (QALYs)
Statistical analysis
Statistical analyses will be performed using SAS version
9.4 (SAS Institute Inc. Cary, NC, USA). All statistical tests
will be two-sided at the 5 % significance level. All treat-
ment evaluations will be performed on the principle of
intention-to-treat (ITT), using the observed data collected
from all randomised participants. Appropriate imputation
methods will be applied to the missing data on the pri-
mary outcome. No imputation will be considered on other
secondary outcomes. A per-protocol analysis may be con-
ducted on the subset of participants who are more com-
pliant with the protocol with pre-defined criteria.
Demographics and baseline characteristics will be sum-
marised using descriptive statistics. Continuous variables
will be summarised as numbers of observed values, mean,
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standard deviation, median, minimum and maximum.
Categorical variables will be described as frequency and
percentage. Information collected on all primary and sec-
ondary outcomes will be first summarised using descrip-
tive statistics at baseline and at 9 months as appropriate.
Results will be presented for each of the two treatment
groups separately. Linear regression model will be used to
test the effect of intervention on the primary outcome be-
tween two groups, adjusting for baseline outcome value,
health district category, type of diabetes, and ethnicity (i.e.
the stratification factors). Model-adjusted means and their
difference will be presented with 95 % confidence inter-
vals. As pre-planned, the analysis will also be conducted
for each health district category separately as stratified,
and the consistency of intervention effects will be tested
in the main model using an interaction term between
treatment group and health district category. A similar
approach will be applied to other continuous secondary
outcomes. Generalised linear regression models will be
applied to categorical outcomes using an appropriate link
function (e.g. a logit link for binary distribution).
Sensitivity analysis may be conducted on the primary
outcome if the proportion of missing data is greater than
10 %. Both single and multiple imputations’ methods
may be considered based on different assumptions on
the missing data, in order to assess the robustness of
treatment evaluation.
If enough participants are recruited, subgroup analyses
by diabetes type and ethnic group will be conducted on
the primary outcome and key secondary outcomes, to
test possible interactions with the intervention.
Discussion
This paper describes the protocol for the SMS4BG trial to
evaluate a text message-based diabetes self-management
support programme compared with usual care. This type
of intervention can provide tailored support between
clinic visits for people with poorly controlled diabetes.
This protocol builds on previous evidence for the role of
mHealth in people with diabetes. The SMS4BG study has
been designed to address limitations of previous diabetes
text message studies. The intervention, developed by a
multidisciplinary team, is comprehensive in design, indi-
vidually tailored, and theoretically grounded, and the
study design will allow for accurate assessment of the im-
pact of this type of intention.
Findings from the pilot study of SMS4BG show that
this type of intervention is acceptable and perceived as
useful by people with diabetes in New Zealand although
the effectiveness must be proven in a rigorously con-
ducted trial. If found to be effective, SMS4BG has the
potential to be implemented into health services across
New Zealand and the potential to be adapted for other
populations.
Trial status
Recruiting: participants are currently being recruited and
enrolled.
Additional files
Additional file 1: List of Behaviour Change Techniques (BCT) utilised in
SMS4BG by grouping (BCT Taxonomy v1). (PDF 67 kb)
Additional file 2: SPIRIT 2013 Checklist. Completed SPIRIT checklist.
(PDF 82 kb)
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